{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:20:28Z","timestamp":1773890428446,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Following the emergency use authorization of BNT162b2 by the Food and Drug administration (FDA) in early December 2020, mRNA- and vector-based vaccines became an important means of reducing the spread and mortality of the COVID-19 pandemic. The European Medicines Agency labelled immune thrombocytopenia (ITP) as a rare adverse reaction of unknown frequency after vector-, but not mRNA-vaccination. Here, we report on the long-term outcome of 6 patients who were diagnosed with de-novo, vaccine-associated ITP (VA-ITP), and on the outcome of subsequent SARS-CoV-2 re-vaccinations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients were included after presenting to our emergency department. Therapy was applied according to ITP guidelines. Follow-up data were obtained from outpatient departments. Both mRNA- or vector-based vaccines were each used in 3 cases, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In all patients, the onset of symptoms occurred after the 1st dose of vaccine was applied. 5 patients required treatment, 3 of them 2nd line therapy. All patients showed a complete response eventually. After up to 359\u00a0days of follow-up, 2 patients were still under 2nd line therapy with thrombopoietin receptor agonists. 5 patients have been re-vaccinated with up to 3 consecutive doses of SARS-CoV-2 vaccines, 4 of them showing stable platelet counts hereafter.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Thrombocytopenia after COVID-19 vaccination should trigger a diagnostic workup to exclude vaccine-induced immune thrombotic thrombocytopenia (VITT) and, if confirmed, VA-ITP should be treated according to current ITP guidelines. Re-vaccination of patients seems feasible under close monitoring of blood counts and using a vaccine that differs from the one triggering the initial episode of VA-ITP.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s15010-022-01909-5","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T16:02:46Z","timestamp":1664899366000},"page":"231-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2451-1070","authenticated-orcid":false,"given":"Michael","family":"Ruzicka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7540-737X","authenticated-orcid":false,"given":"Sonja","family":"Wurm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3708-8264","authenticated-orcid":false,"given":"Lars","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0358-5249","authenticated-orcid":false,"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1952-052X","authenticated-orcid":false,"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-2127","authenticated-orcid":false,"given":"Stefan","family":"Boeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Giessen-Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Milani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8751-8555","authenticated-orcid":false,"given":"Joachim H.","family":"Stemmler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-9469","authenticated-orcid":false,"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0987-7373","authenticated-orcid":false,"given":"Oliver","family":"Weigert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5139-4957","authenticated-orcid":false,"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"1909_CR1","unstructured":"WHO. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed 10 May 2022."},{"key":"1909_CR2","doi-asserted-by":"publisher","unstructured":"Greinacher A, Selleng K, Wesche J, Handtke S, Palankar R, Aurich K, et al. 2021. Towards Understanding ChAdOx1 nCov-19 Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT). Res Sq 1\u201313. https:\/\/doi.org\/10.21203\/rs.3.rs-440461\/v1.","DOI":"10.21203\/rs.3.rs-440461\/v1"},{"key":"1909_CR3","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/nejmoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384:2092\u2013101. https:\/\/doi.org\/10.1056\/nejmoa2104840.","journal-title":"N Engl J Med"},{"key":"1909_CR4","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1172\/JCI200114235","volume":"108","author":"KW Wucherpfennig","year":"2001","unstructured":"Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Investig. 2001;108:1097\u2013104. https:\/\/doi.org\/10.1172\/JCI200114235.","journal-title":"J Clin Investig"},{"key":"1909_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.phrs.2014.08.002","volume":"92","author":"A Soriano","year":"2015","unstructured":"Soriano A, Nesher G, Shoenfeld Y. Predicting post-vaccination autoimmunity: who might be at risk? Pharmacol Res. 2015;92:18\u201322. https:\/\/doi.org\/10.1016\/j.phrs.2014.08.002.","journal-title":"Pharmacol Res"},{"key":"1909_CR6","doi-asserted-by":"publisher","first-page":"108480","DOI":"10.1016\/j.clim.2020.108480","volume":"217","author":"A Vojdani","year":"2020","unstructured":"Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480. https:\/\/doi.org\/10.1016\/j.clim.2020.108480.","journal-title":"Clin Immunol"},{"key":"1909_CR7","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1007\/s42399-020-00521-8","volume":"2","author":"S Bhattacharjee","year":"2020","unstructured":"Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID-19: a systematic review. SN Compr Clin Med. 2020;2:2048\u201358. https:\/\/doi.org\/10.1007\/s42399-020-00521-8.","journal-title":"SN Compr Clin Med"},{"key":"1909_CR8","doi-asserted-by":"publisher","first-page":"108665","DOI":"10.1016\/j.clim.2021.108665","volume":"224","author":"R Talotta","year":"2021","unstructured":"Talotta R. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to \u201cpotential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.\u201d Clin Immunol. 2021;224:108665.","journal-title":"Clin Immunol"},{"key":"1909_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jcpa.2007.04.013","volume":"137","author":"S Goriely","year":"2007","unstructured":"Goriely S, Goldman M. From tolerance to autoimmunity: is there a risk in early life vaccination? J Comp Pathol. 2007;137:57\u201361. https:\/\/doi.org\/10.1016\/j.jcpa.2007.04.013.","journal-title":"J Comp Pathol"},{"key":"1909_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines9050435","volume":"9","author":"A Watad","year":"2021","unstructured":"Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, et al. Immune-mediated disease flares or new-onset disease in 27 subjects following MRNA\/DNA SARS-Cov-2 vaccination. Vaccines. 2021;9:1\u201323. https:\/\/doi.org\/10.3390\/vaccines9050435.","journal-title":"Vaccines"},{"key":"1909_CR11","doi-asserted-by":"publisher","unstructured":"Mingot-Castellano ME, Butta N, Canaro M, Gomez Del Castillo Solano MDC, Sanchez-Gonzalez B, Jimenez-Barcenas R et al. COVID-19 Vaccines and Autoimmune Hematologic Disorders. Vaccines (Basel). 2022;10(6). https:\/\/doi.org\/10.3390\/vaccines10060961","DOI":"10.3390\/vaccines10060961"},{"key":"1909_CR12","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1016\/j.vaccine.2021.04.054","volume":"39","author":"K.J. Welsh JBWC,","year":"2021","unstructured":"K.J. Welsh JBWC, et al. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2021;39:3329\u201332.","journal-title":"Vaccine"},{"key":"1909_CR13","doi-asserted-by":"publisher","first-page":"E133","DOI":"10.1002\/ajh.26106","volume":"96","author":"O Tarawneh","year":"2021","unstructured":"Tarawneh O, Tarawneh H. Immune thrombocytopenia in a 22-year-old post COVID-19 vaccine. Am J Hematol. 2021;96:E133\u20134. https:\/\/doi.org\/10.1002\/ajh.26106.","journal-title":"Am J Hematol"},{"key":"1909_CR14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/ajh.26132","volume":"96","author":"EJ Lee","year":"2021","unstructured":"Lee EJ, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol. 2021;96:534\u20137. https:\/\/doi.org\/10.1002\/ajh.26132.","journal-title":"Am J Hematol"},{"key":"1909_CR15","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1182\/blood.2021013411","volume":"139","author":"EJ Lee","year":"2022","unstructured":"Lee EJ, Beltrami-Moreira M, Al-Samkari H, Cuker A, DiRaimo J, Gernsheimer T, et al. SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Blood. 2022;139:1564\u201374. https:\/\/doi.org\/10.1182\/blood.2021013411.","journal-title":"Blood"},{"key":"1909_CR16","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","volume":"16","author":"S Audia","year":"2017","unstructured":"Audia S, Mah\u00e9vas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017;16:620\u201332. https:\/\/doi.org\/10.1016\/j.autrev.2017.04.012.","journal-title":"Autoimmun Rev"},{"key":"1909_CR17","unstructured":"EMA. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27\u201330 September 2021. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-27-30-september-2021. Accessed May 17 2022."},{"key":"1909_CR18","unstructured":"Begley A. Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, September 2021. https:\/\/www.europeanpharmaceuticalreview.com\/news\/163682\/pharmacovigilance-risk-assessment-committee-prac-meeting-highlights-september-2021-2\/. Accessed 17 May 2022."},{"key":"1909_CR19","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/bloodadvances.2021006379","volume":"6","author":"C Visser","year":"2022","unstructured":"Visser C, Swinkels M, van Werkhoven ED, Croles FN, Noordzij-Nooteboom HS, Eefting M, et al. COVID-19 vaccination in patients with immune thrombocytopenia. Blood Adv. 2022;6:1637\u201344. https:\/\/doi.org\/10.1182\/bloodadvances.2021006379.","journal-title":"Blood Adv"},{"issue":"3","key":"1909_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/bjh.17645","volume":"195","author":"DJ Kuter","year":"2021","unstructured":"Kuter DJ. Exacerbation of immune thrombocytopenia following COVID-19 vaccination. Br J Haematol. 2021;195(3):365\u201370. https:\/\/doi.org\/10.1111\/bjh.17645.","journal-title":"Br J Haematol"},{"key":"1909_CR21","unstructured":"Robert-Koch-Institut. Digitales Impfquotenmonitoring zur COVID-19-Impfung. 06.05.2022 ed. https:\/\/www.rki.de\/DE\/Content\/InfAZ\/N\/Neuartiges_Coronavirus\/Daten\/Impfquoten-Tab.html. Accessed 08.05.2022."},{"key":"1909_CR22","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386\u201393. https:\/\/doi.org\/10.1182\/blood-2008-07-162503.","journal-title":"Blood"},{"key":"1909_CR23","doi-asserted-by":"publisher","unstructured":"Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Grossman BJ, Mintz PD, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162(3):205-13. https:\/\/doi.org\/10.7326\/M14-1589.","DOI":"10.7326\/M14-1589"},{"key":"1909_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000492187","volume":"41","author":"A Matzdorff","year":"2018","unstructured":"Matzdorff A, Meyer O, Ostermann H, Kiefel V, Eberl W, K\u00fchne T, et al. Immune Thrombocytopenia - current diagnostics and therapy: recommendations of a joint working group of DGHO, \u00d6GHO, SGH, GPOH, and DGTI. Oncol Res Treat. 2018;41:1\u201330. https:\/\/doi.org\/10.1159\/000492187.","journal-title":"Oncol Res Treat"},{"key":"1909_CR25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s12026-014-8597-x","volume":"60","author":"C Perricone","year":"2014","unstructured":"Perricone C, Ceccarelli F, Nesher G, Borella E, Odeh Q, Conti F, et al. Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases. Immunol Res. 2014;60:226\u201335. https:\/\/doi.org\/10.1007\/s12026-014-8597-x.","journal-title":"Immunol Res"},{"key":"1909_CR26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ijid.2020.07.085","volume":"99","author":"P David","year":"2020","unstructured":"David P, Shoenfeld Y. ITP following vaccination. Int J Infect Dis. 2020;99:243\u20134. https:\/\/doi.org\/10.1016\/j.ijid.2020.07.085.","journal-title":"Int J Infect Dis"},{"issue":"7","key":"1909_CR27","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s41591-021-01419-1","volume":"27","author":"AM Pishko","year":"2021","unstructured":"Pishko AM, Bussel JB, Cines DB. COVID-19 vaccination and immune thrombocytopenia. Nat Med. 2021;27(7):1145\u20136. https:\/\/doi.org\/10.1038\/s41591-021-01419-1.","journal-title":"Nat Med"},{"key":"1909_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26366","author":"AD Jiang","year":"2021","unstructured":"Jiang AD, Portuguese AJ, Weatherford A. Platelet trends after COVID-19 vaccination in patients with chronic or persistent immune thrombocytopenia. Am J Hematol. 2021. https:\/\/doi.org\/10.1002\/ajh.26366.","journal-title":"Am J Hematol"},{"key":"1909_CR29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013411","author":"E-J Lee","year":"2021","unstructured":"Lee E-J, Beltrami Moreira M, Al-Samkari H, Cuker A, DiRaimo J, Gernsheimer T, et al. SARS-CoV-2 Vaccination and Immune Thrombocytopenia in de novo and pre-existing ITP patients. Blood. 2021. https:\/\/doi.org\/10.1182\/blood.2021013411.","journal-title":"Blood"},{"key":"1909_CR30","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1182\/blood.2021012479","volume":"138","author":"F-o Paulsen","year":"2021","unstructured":"Paulsen F-o, Schaefers C, Langer F, Frenzel C, Wenzel U, Hengel FE, et al. Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine ( ChAdOx1 nCov-19). Blood. 2021;138:996\u20139. https:\/\/doi.org\/10.1182\/blood.2021012479.","journal-title":"Blood"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-022-01909-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-022-01909-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-022-01909-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T15:09:49Z","timestamp":1674745789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-022-01909-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1909"],"URL":"https:\/\/doi.org\/10.1007\/s15010-022-01909-5","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]},"assertion":[{"value":"14 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing financial or non-financial interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional ethics committee of the LMU Klinikum (project number: 21\u20130594) and performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}